BIND Therapeutics initiated with Outperform
April 07, 2015 at 16:49 PM EDT
Oppenheimer
initiated coverage of BIND Therapeutics Inc. (Nasdaq: BIND) with an
Outperform rating and a price target of $14. The stock price gained 65
cents to close at $6.32.
